Cite
HARVARD Citation
Bennett, S. et al. (2022). Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet infectious diseases. 22 (9), pp. 1343-1355. [Online].